Results 31 to 40 of about 9,061 (176)

DataSheet1_Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells.ZIP

, 2022
Abemaciclib is a cyclin-dependent kinases 4/6 (CDK4/6) inhibitor approved for the treatment of metastatic breast cancer. Preclinical studies suggest that abemaciclib has the potential for lung cancer treatment.
Cun-Wu Chen (12910838), Milton Talukder (5950043), Chao-Yue Sun (5392448), Di Cao (839887)   +3 more
core   +1 more source

Image1_Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells.tif

, 2022
Abemaciclib is a cyclin-dependent kinases 4/6 (CDK4/6) inhibitor approved for the treatment of metastatic breast cancer. Preclinical studies suggest that abemaciclib has the potential for lung cancer treatment.
Cun-Wu Chen (12910838), Milton Talukder (5950043), Chao-Yue Sun (5392448), Di Cao (839887)   +3 more
core   +1 more source

Abemaciclib-associated Diarrhea: An Exploratory Analysis of Real-life Data

, 2023
Background/Aim: Abemaciclib is a cyclin-dependent kinase 4/6 inhibitor approved in combination with endocrine therapy for treating hormone receptor-positive and human epidermal growth factor receptor 2-negative early and advanced breast cancer patients ...
Gebbia V., Valerio M. R., Sano M. V., Vigneri P., Martorana F., Caruso M., Piazza D., Giotta F., Spada M.   +8 more
core   +1 more source

Study on the Biological Function of Abemecilib in Inhibiting the Proliferation, Invasion and
Migration of Small Cell Lung Cancer with High c-Myc Expression

Chinese Journal of Lung Cancer, 2023
Background and objective Small cell lung cancer (SCLC) with high c-Myc expression is prone to relapse and metastasis, leading to extremely low survival rate.
Jingjing GUO, Di MU, Wenwen YU, Leina SUN, Jiali ZHANG, Xiubao REN, Ying HAN   +6 more
doaj   +1 more source

Cost-Effectiveness of Abemaciclib in Early Breast Cancer Patients: One Size Fits All or Tailoring to Patients’ Needs? [PDF]

, 2023
Purpose: The addition of two years of abemaciclib treatment to standard adjuvant endocrine therapy in all patients with high risk ER+, HER2-early breast cancer (EBC) has been approved by the US Food and Drug Administration (FDA).
Jager, Agnes, Jongbloed, Elisabeth M., Groot, Carin A.Uyl De, van Schoubroeck, Hannah M., Uyl-de Groot, Carin, Blommestein, Hedwig M., Martens, John W.M., Wilting, Saskia M.; id_orcid, Blommestein, Hedwig M.; id_orcid, Wilting, Saskia M.   +9 more
core   +2 more sources

Identification of abemaciclib derivatives targeting cyclin-dependent kinase 4 and 6 using molecular dynamics, binding free energy calculation, synthesis, and pharmacological evaluation

Frontiers in Pharmacology, 2023
CDK4/6 plays a crucial role in various cancers and is an effective anticancer drug target. However, the gap between clinical requirements and approved CDK4/6 drugs is unresolved.
Yanting Zhou, Xiandeng Li, Peifang Luo, Huiting Chen, Yan Zhou, Xueting Zheng, Yuan Yin, Haoche Wei, Hongji Liu, Wen Xia, Mingsong Shi, Xiaoan Li   +11 more
doaj   +1 more source

Refractory diarrhea in a patient with metastatic breast cancer with ABCB1 polymorphism: A case report

Current Problems in Cancer: Case Reports
Although abemaciclib is an essential therapy for breast cancer, approximately 80 % of patients develop diarrhea. Abemaciclib undergoes excretion by the P-glycoprotein encoded by ATP-binding cassette subfamily B member 1 (ABCB1) in the small intestine ...
Moeko Iida, Yoshihiko Tasaki, Akiko Kato, Tomoya Yasujima, Hiroaki Yuasa, Yasuhiro Maeda, Yoshihisa Mimura, Kunihiro Odagiri, Yuka Kimura, Nanami Ito, Yasuhiro Horita, Yosuke Sugiyama, Yuji Hotta, Tatsuya Toyama, Yoko Furukawa-Hibi   +14 more
doaj   +1 more source

Abemaciclib as an original inhibitor of cyclin-dependent kinase for the treatment of luminal HER2-negative disseminated breast cancer

Медицинский совет, 2020
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, namely palbociclib, ribociclib and abemaciclib, have become a new standard of treatment of patients with hormone receptor-positive, HER2-negative disseminated or metastatic breast cancer (HR+ HER2- MBC ...
N. S. Besova
doaj   +1 more source

CDK4/6 blockade provides an alternative approach for treatment of mismatch-repair deficient tumors

OncoImmunology, 2022
Mismatch repair-deficient (dMMR) tumors show a good response toward immune checkpoint inhibitors (ICI), but developing resistance impairs patients’ outcomes.
Inken Salewski, Julia Henne, Leonie Engster, Paula Krone, Bjoern Schneider, Caterina Redwanz, Heiko Lemcke, Larissa Henze, Christian Junghanss, Claudia Maletzki   +9 more
doaj   +1 more source

Utilization and Safety of Concurrent Use of Abemaciclib and Radiation Therapy Among Patients With HR+, HER2− Metastatic Breast Cancer in the Real-World Setting

Advances in Radiation Oncology
Purpose: Real-world data on tolerability of concurrent radiation therapy (RT) and abemaciclib are limited. This study described real-world utilization and safety of concurrent RT and abemaciclib in patients with hormone receptor-positive (HR+) and human ...
Wambui Gathirua-Mwangi, PhD, MPH, Sangmi Kim, PhD, MS, Holly Martin, PhD, Tasneem Lokhandwala, PhD, Shen Zheng, PhD, Eileen Farrelly, MPH, Erich Brechtelsbauer, PharmD, Sarah Rybowski, MD, Kamran A. Ahmed, MD   +8 more
doaj   +1 more source